Insider Transactions in Q2 2023 at Biogen Inc. (BIIB)
Insider Transaction List (Q2 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 30
2023
|
Robin Kramer Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
122
-2.98%
|
$34,648
$284.85 P/Share
|
|
Jun 30
2023
|
Robin Kramer Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
252
+5.8%
|
-
|
|
Jun 30
2023
|
Rachid Izzar Head of Global Product Strat. |
SELL
Payment of exercise price or tax liability
|
Direct |
244
-3.82%
|
$69,296
$284.85 P/Share
|
|
Jun 30
2023
|
Rachid Izzar Head of Global Product Strat. |
BUY
Exercise of conversion of derivative security
|
Direct |
504
+7.31%
|
-
|
|
Jun 30
2023
|
Priya Singhal Head of Development |
SELL
Payment of exercise price or tax liability
|
Direct |
153
-4.84%
|
$43,452
$284.85 P/Share
|
|
Jun 30
2023
|
Priya Singhal Head of Development |
BUY
Exercise of conversion of derivative security
|
Direct |
315
+9.07%
|
-
|
|
Jun 26
2023
|
Stephen A Sherwin Director |
BUY
Grant, award, or other acquisition
|
Direct |
960
+4.87%
|
-
|
|
Jun 26
2023
|
Jesus B Mantas Director |
BUY
Grant, award, or other acquisition
|
Direct |
960
+13.7%
|
-
|
|
Jun 26
2023
|
Eric K Rowinsky Director |
BUY
Grant, award, or other acquisition
|
Direct |
960
+4.54%
|
-
|
|
Jun 26
2023
|
Maria C Freire Director |
BUY
Grant, award, or other acquisition
|
Direct |
960
+23.62%
|
-
|
|
Jun 26
2023
|
William A Hawkins Director |
BUY
Grant, award, or other acquisition
|
Direct |
960
+15.71%
|
-
|
|
Jun 26
2023
|
Susan Langer Director |
BUY
Grant, award, or other acquisition
|
Direct |
960
+40.35%
|
-
|
|
Jun 26
2023
|
Caroline Dorsa Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,580
+5.98%
|
-
|
|
Apr 28
2023
|
Ginger Gregory EVP, Human Resources |
SELL
Open market or private sale
|
Direct |
2,681
-24.02%
|
$804,300
$300.0 P/Share
|
|
Apr 04
2023
|
Priya Singhal Head of Development |
SELL
Open market or private sale
|
Direct |
91
-3.1%
|
$25,207
$277.11 P/Share
|